When stem cells are injected into thick tissues, they often clump together and die from lack of oxygen or nutrients, making ...

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker 'MSLE” on Feb. 6 ...

Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and Secretome Therapeutics (Secretome) are ...

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a place ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early ...

A donation box meant to help a sick child was stolen from the entrance of Stara Zagora Zoo, authorities confirmed after ...

Delhi's new genetic screening programme aims to save newborn lives. Know why you need to identify risks before they start. In ...

Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...

Novartis AG faces major patent expiries but is buying pipeline assets to sustain growth. Click for this NVS update.

Sarepta plans to ask the FDA for full approval of exon-skipping Duchenne muscular dystrophy treatments Amondys 45 and Vyondys 53.